CSL Gestion

Gestion contrôle des critères 1/4

Le PDG CSL est Paul McKenzie, nommé en Mar2023, a un mandat de 1.67 ans. La rémunération annuelle totale est $ 8.18M, composée du salaire de 23.1% et des bonus 76.9%, y compris les actions et options de la société. détient directement 0.005% des actions de la société, d'une valeur de A$ 6.44M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.7 ans et 4.9 ans.

Informations clés

Paul McKenzie

Directeur général

US$8.2m

Rémunération totale

Pourcentage du salaire du PDG	23.1%
Durée du mandat du directeur général	1.7yrs
Propriété du PDG	0.005%
Durée moyenne d'occupation des postes de direction	1.7yrs
Durée moyenne du mandat des membres du conseil d'administration	4.9yrs

Mises à jour récentes de la gestion

Recent updates

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

Nov 01

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Oct 05

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Analyse de la rémunération des PDG

Comment la rémunération de Paul McKenzie a-t-elle évolué par rapport aux bénéfices de CSL?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Rémunération vs marché: La rémunération totale de Paul ($USD 8.18M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 4.40M ).

Rémunération et revenus: La rémunération de Paul a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Paul McKenzie (58 yo)

1.7yrs

Titularisation

US$8,183,842

Compensation

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Paul McKenzie	MD, CEO & Executive Director	1.7yrs	US$8.18m	0.0047% A$ 6.4m
Joy Linton	Interim Executive Vice President of CSL Behring	less than a year	US$3.73m	0.0025% A$ 3.4m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.3yrs	US$4.07m	0.00044% A$ 598.1k
John A. Levy	Interim Chief Financial Officer	less than a year	pas de données	pas de données
Chris Cooper	Head of Investor Relations	no data	pas de données	pas de données
Gregory Boss	Executive VP of Legal & General Counsel	15.8yrs	US$2.31m	pas de données
Roanne Parry	Chief Human Resources Officer	less than a year	pas de données	pas de données
Andrew Nash	Senior Vice President of Research	no data	pas de données	pas de données
William Mezzanotte	Executive VP & Head of Research and Development	6.1yrs	US$2.14m	pas de données
Mark Hill	Chief Digital Information Officer & Executive VP	4.1yrs	pas de données	pas de données
Deirdre BeVard	Senior Vice President of Research & Development Strategic Operations	no data	pas de données	pas de données
Herve Gisserot	Senior VP & GM of Vifor	1.7yrs	pas de données	pas de données

1.7yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CSL n'est pas considérée comme expérimentée (ancienneté moyenne 1.7 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Paul McKenzie	MD, CEO & Executive Director	1.9yrs	US$8.18m	0.0047% A$ 6.4m
Megan Clark	Independent Non Executive Director	8.8yrs	US$242.44k	0.0011% A$ 1.5m
Alison Watkins	Independent Non-Executive Director	3.3yrs	US$240.56k	0.00077% A$ 1.0m
Carolyn Hewson	Independent Non-Executive Director	4.9yrs	US$237.09k	0.00047% A$ 638.9k
Brian McNamee	Independent Non-Executive Chairman	6.8yrs	US$604.85k	0.026% A$ 35.5m
Robert Cuthbertson	Non-Independent Non-Executive Director	6.1yrs	US$221.35k	0.015% A$ 19.8m
Marie McDonald	Independent Non-Executive Director	11.3yrs	US$215.19k	0.00088% A$ 1.2m
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% A$ 557.3k
Elaine Sorg	Independent Non-Executive Director	less than a year	pas de données	pas de données

4.9yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CSL sont considérés comme expérimentés (ancienneté moyenne 4.9 ans).

CSL Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

With EPS Growth And More, CSL (ASX:CSL) Makes An Interesting Case

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Independent Non Executive Director recently bought AU$74k worth of stock

Consensus forecasts updated

Now 20% undervalued

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Now 20% undervalued